192 related articles for article (PubMed ID: 24333643)
21. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
Corrêa MF; Fernandes JP
Curr Protein Pept Sci; 2016; 17(3):213-9. PubMed ID: 26427385
[TBL] [Abstract][Full Text] [Related]
22. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
Cynamon MH; Gimi R; Gyenes F; Sharpe CA; Bergmann KE; Han HJ; Gregor LB; Rapolu R; Luciano G; Welch JT
J Med Chem; 1995 Sep; 38(20):3902-7. PubMed ID: 7562923
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
24. [Relation between chemical structure and antimycobacterial activity against atypical strains. XIII. Thiosalicylanilides].
Waisser K; Kubicová L; Gregor J; Budová J; Andrlová A; Drsata J; Odlerová Z
Ceska Slov Farm; 1998 Mar; 47(2):84-6. PubMed ID: 9650366
[TBL] [Abstract][Full Text] [Related]
25. In vitro antibacterial and antifungal activity of salicylanilide pyrazine-2-carboxylates.
Krátký M; Vinšová J; Buchta V
Med Chem; 2012 Jul; 8(4):732-41. PubMed ID: 22548336
[TBL] [Abstract][Full Text] [Related]
26. In vitro biological evaluation of new antimycobacterial salicylanilide-tuftsin conjugates.
Baranyai Z; Krátký M; Vosátka R; Szabó E; Senoner Z; Dávid S; Stolaříková J; Vinšová J; Bősze S
Eur J Med Chem; 2017 Jun; 133():152-173. PubMed ID: 28384546
[TBL] [Abstract][Full Text] [Related]
27. Salicylanilide ester prodrugs as potential antimicrobial agents--a review.
Krátký M; Vinsová J
Curr Pharm Des; 2011; 17(32):3494-505. PubMed ID: 22074422
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis, Antimycobacterial Evaluation, and In Silico Studies of 3-(Phenylcarbamoyl)-pyrazine-2-carboxylic Acids.
Semelková L; Janošcová P; Fernandes C; Bouz G; Janďourek O; Konečná K; Paterová P; Navrátilová L; Kuneš J; Doležal M; Zitko J
Molecules; 2017 Sep; 22(9):. PubMed ID: 28880230
[TBL] [Abstract][Full Text] [Related]
29. Antimycobacterial activity of a series of pyrazinoic acid esters.
Cynamon MH; Klemens SP; Chou TS; Gimi RH; Welch JT
J Med Chem; 1992 Apr; 35(7):1212-5. PubMed ID: 1560435
[TBL] [Abstract][Full Text] [Related]
30. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
31. In vitro antibacterial and antifungal activity of salicylanilide benzoates.
Krátký M; Vinšová J; Buchta V
ScientificWorldJournal; 2012; 2012():290628. PubMed ID: 22666101
[TBL] [Abstract][Full Text] [Related]
32. [In vitro activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis, M. avium, M. africanum, M. kansasii and BCG strains].
Thomas L; Naumann P; Crea A
Immun Infekt; 1986 Nov; 14(6):203-7. PubMed ID: 3100424
[TBL] [Abstract][Full Text] [Related]
33. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
[TBL] [Abstract][Full Text] [Related]
34. In vitro antimycobacterial activities of pyrazinamide analogs.
Yamamoto S; Toida I; Watanabe N; Ura T
Antimicrob Agents Chemother; 1995 Sep; 39(9):2088-91. PubMed ID: 8540721
[TBL] [Abstract][Full Text] [Related]
35. New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains.
Imramovský A; Vinsová J; Férriz JM; Dolezal R; Jampílek J; Kaustová J; Kunc F
Bioorg Med Chem; 2009 May; 17(10):3572-9. PubMed ID: 19403314
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
Seitz LE; Suling WJ; Reynolds RC
J Med Chem; 2002 Dec; 45(25):5604-6. PubMed ID: 12459027
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the structure and antimycobacterial activity of substituted salicylanilides.
Waisser K; Bures O; Holý P; Kunes J; Oswald R; Jirásková L; Pour M; Klimesová V; Kubicová L; Kaustová J
Arch Pharm (Weinheim); 2003 Mar; 336(1):53-71. PubMed ID: 12666254
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
[TBL] [Abstract][Full Text] [Related]
39. The oriented development of antituberculotics: salicylanilides.
Waisser K; Matyk J; Divisová H; Husáková P; Kunes J; Klimesová V; Kaustová J; Möllmann U; Dahse HM; Miko M
Arch Pharm (Weinheim); 2006 Nov; 339(11):616-20. PubMed ID: 17048291
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.
Zitko J; Paterová P; Kubíček V; Mandíková J; Trejtnar F; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2013 Jan; 23(2):476-9. PubMed ID: 23237840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
